BPC-157 Evidence: What the Human Studies Actually Show
BPC-157 has a reputation that arrived long before its evidence did. It is discussed in gyms, on podcasts and across a whole tier of supplement sites as a healing peptide, often with a confidence that the published literature does not support anywhere.
Here is the shape of that literature in one sentence: the great majority of BPC-157 research has been done in rats and mice, the human trials are few, small and mostly two decades old, and nothing has been studied in people for the uses BPC-157 is most often sold for. That is not a reason to dismiss it. It is a reason to be precise about what is known, which is what this page is for. The main page covers what the peptide is; the regulatory status page covers where it sits with the FDA, which is its own moving story.
Where BPC-157 came from
BPC-157 is a synthetic chain of fifteen amino acids, copied from a sequence found in a protein in human gastric juice. The parent protein was named Body Protection Compound, which is where the initials come from, and the fragment was identified in Zagreb in the 1990s by a research group at the University of Zagreb led by Predrag Sikirić.
That origin story is the source of the idea that runs through everything written about this peptide: that the stomach produces something protective, and that isolating it might let you apply the same protection elsewhere in the body. It is a genuinely interesting hypothesis. It has been tested almost entirely in animals.
What the animal work shows
The preclinical literature on BPC-157 is large. Published papers run well into the hundreds, and they cover an unusually wide range of injury models: gastric and intestinal lesions, ulcerative colitis, esophageal damage, severed tendons, crushed muscle, transected ligaments, fractured bone, damaged nerves, corneal wounds and several kinds of vascular injury.
Within those models the findings are consistent. Treated animals tend to show faster tissue repair, less inflammation and better functional recovery than untreated controls. Proposed mechanisms cluster around blood vessel growth, the nitric oxide system, growth factor signaling and an effect on collagen organization.
Three caveats belong next to that, and they are the reason this page exists.
A large share of the work comes from one place. A striking proportion of the positive literature traces back to the original Zagreb group and its collaborators. That is not an accusation of anything. It is a recognized weakness in an evidence base, because independent replication in other laboratories is how a preclinical finding earns confidence, and BPC-157 has less of that than its publication count suggests.
Rodent healing models are generous. Animals in these experiments are young, genetically similar, uninjured before the experiment begins, and healing in a controlled environment. A tendon model in a rat is not a middle-aged human shoulder with fifteen years of wear in it. Compounds that accelerate healing in small animals have failed to do so in people many times before.
Breadth is a flag, not a feature. A substance reported to help every tissue in every model is either a profound discovery or a sign of publication patterns that favor positive results. Both possibilities are live, and the way to tell them apart is human trials.
What the human work shows
This is the short section, and its shortness is the finding.
The human trials that exist came out of a pharmaceutical development program in the late 1990s and 2000s, when the peptide was being developed as a drug candidate for inflammatory bowel disease under a code name rather than as BPC-157. That program ran early-phase safety work and at least one controlled trial in ulcerative colitis. The safety signal that came out of it was reassuring, and the program did not continue to approval. A substantial part of what was reported appeared in conference abstracts rather than in full peer-reviewed papers, which makes it hard to assess properly.
Beyond that there is very little. As of this writing there is no published randomized controlled trial of BPC-157 in humans for tendon injury, ligament injury, muscle recovery, joint pain, post-surgical healing or athletic performance — which is to say, for almost every reason people look for it.
Why the gap between the two matters
Several things sit in that gap, and each one is a real obstacle rather than a technicality.
Route and absorption. Much of the animal work used injected peptide. Whether an orally taken version survives digestion intact and reaches tissue in a meaningful way is a separate question from whether the molecule does anything, and it has not been settled in people.
Product identity. A great deal of the BPC-157 sold online is labeled for research use only, which means no one has verified its identity, purity or content. Independent testing of peptides bought this way has repeatedly found products that were not what the label said. When the material is uncertain, any personal experience with it is uninterpretable.
Long-term safety is unstudied. Short exposure in small trials and short exposure in rodents tell you very little about taking something for months or years. The mechanisms most often proposed for BPC-157 involve blood vessel growth and tissue proliferation, and anything that promotes those pathways deserves long-term data before it is treated as routine. There is no human evidence of harm here. There is also no human evidence of safety over time, and the honest word for that is unknown.
Competitive sport prohibits it. BPC-157 appears on the World Anti-Doping Agency's prohibited list as a non-approved substance. Anyone subject to testing should treat it as disqualifying.
What would change the picture
A well-run randomized trial in humans, in a defined injury, with a real control group and a functional endpoint, published in full. That is the whole list. Until something like it exists, BPC-157 is a compound with an interesting mechanism, a large animal literature, a thin human record and no approved use — and a page that says otherwise is selling something.
Frequently asked questions
In rodent injury models it consistently outperforms no treatment. In humans, it has not been tested for the uses it is best known for, so the honest answer is that nobody knows yet.
A small number, from a drug development program in the late 1990s and 2000s aimed at inflammatory bowel disease. They were early-phase, small, and largely reported in abstract form. No published human trial covers tendon, muscle or joint healing.
Because nearly all of it is preclinical. Volume of publication is not the same as strength of evidence, and a large share of this literature comes from a single research group without wide independent replication.
Short-term human exposure in the early trials did not raise safety concerns, and animal work has not shown toxicity. Long-term safety in people has never been studied, and that gap is real rather than reassuring.
Two problems. Most material sold online is unverified research-use-only product, so you cannot know what you took. And healing has its own timeline, which makes a personal trial without a comparison almost impossible to read.
It appears on the World Anti-Doping Agency's prohibited list as a non-approved substance. Tested athletes should assume it is disqualifying.
Where this fits in your plan
Read the regulatory status page next, because the legal picture around this peptide changed twice in 2026 and it shapes what is realistically available. If your interest is gastrointestinal, the gut health page covers the part of the research with the most preclinical support. The peptide therapy overview explains how we think about this category generally.
We measure first. Then we act.
References
- Sikirić P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design 2011;17(16):1612–1632.
- Seiwerth S, Rucman R, Turkovic B, et al. BPC 157 and standard angiogenic growth factors. Gastrointestinal tract healing, lessons from tendon, ligament, muscle and bone healing. Current Pharmaceutical Design 2018;24(18):1972–1989.
- Veljača M, Pavić Sladoljev D, Mildner B, et al. Safety, tolerability and pharmacokinetics of PL 14736, a novel agent for treatment of ulcerative colitis, in healthy male volunteers. Gut 2003;51(Suppl III):A309.
- Chang CH, Tsai WC, Lin MS, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology 2011;110(3):774–780.
- World Anti-Doping Agency. Prohibited List — section S0, non-approved substances.
- Xu C, Sun L, Ren F, et al. Preclinical safety evaluation of body protective compound-157. Experimental and Therapeutic Medicine 2020;20(5):4.
- Back toBPC-157
- BPC-157 regulatory statusBPC-157 is not FDA-approved. Its status changed twice in 2026 and is still unsettled. What the April removal and the July committee vote actually did.Read
- BPC-157 and gut healthThe gut is where BPC-157 research started and where it is strongest. It is also still preclinical, with no approved indication. An honest look.Read
How we write and review our content
ACT 2 Health provides clinician-led care. Treatments are available only to eligible patients following clinical evaluation and within applicable regulations. This content is educational and is not medical advice. Individual results vary.
Compounded medication. Prepared by a licensed compounding pharmacy under a prescription written for you. Compounded medications are not FDA-approved, are not reviewed by the FDA for safety or effectiveness, and are not equivalent to or interchangeable with any branded product. Prescribed only when a licensed provider determines it is medically appropriate.
Care is delivered via telemedicine by healthcare professionals licensed in the state where the patient is located. Services are available only in states where our providers are licensed.